SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: HardToFind who wrote (10193)5/8/2018 12:17:44 PM
From: mattstat  Respond to of 12873
 
If Diwan wants to extract the maximum cash from NNVC, I suspect he would actually be better of by lowering the royalty. He is in serious risk of killing his fundraising arm, TC's host.

I think it's clear, between NNVC and TheraCour, where Diwan's loyalties lie.
I agree 100%!



To: HardToFind who wrote (10193)5/8/2018 12:36:25 PM
From: BoredMember  Read Replies (2) | Respond to of 12873
 
Again, I must say that you are using the stock price and shareholder return as your measure of success. That is not what I believe Dr. Anil Diwan is measuring success by.

If Nanoviricides is the primary source of revenue for Theracour as you profess, then surely Nonoviricides is extremely important to Theracour and Dr. Anil Diwan.

Isn't that abundantly clear?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News